A new era in infectious disease diagnostics
Delve Bio is on a mission to revolutionize infectious disease testing by bringing metagenomic (mNGS) testing out of the research lab and into the clinic. Founded by some of the world’s foremost experts in infectious disease, Delve Bio is ending the era of guess and test, enabling clinicians to test once and know.
Pioneers with purpose
At Delve, we are scaling our proprietary, ground-breaking metagenomic sequencing (mNGS) technology to give labs and clinicians the tool they need to move from “what’s wrong” to “what’s next.” Our team includes some of the most experienced and respected researchers, clinicians, investors and entrepreneurs in the world, working together to make mNGS diagnostics standard of care.
Meet the Delve Team
Pardis Sabeti, MD, PhD
Professor, Harvard University
Institute Member, Broad Institute
https://www.sabetilab.org
Joe DeRisi, PhD
Professor, University of California San Francisco
President, Chan Zuckerberg Biohub
https://derisilab.ucsf.edu
Matthew Meyerson, MD, PhD
Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Institute Member, Cancer Program, Broad Institute
https://meyersonlab.dana-farber.org
Charles Chiu, MD, PhD
Professor, Laboratory Medicine and Medicine / Infectious Diseases, University of California, San Francisco
Associate Director, UCSF Clinical Microbiology Laboratory
Investigator, Chan-Zuckerberg Biohub
https://chiulab.ucsf.edu
Investors
Perceptive Xontogeny Venture Fund II
Section 32
Google Ventures
Working with leading hospitals
Leading institutions across the country use the power of metagenomics to deliver answers for their patients.